INDBInternet News Database 2.5 Updated 1 min ago · 306 sources Show or hide images Light or dark

Results for “Novo's Wegovy”

Health
2 sources

Who is covering this

ReutersCenterAmherst BeeNot rated
Truth score 57
Centre 100%100%
ReutersCenter

Lilly says its obesity drugs helped patients lose weight in clinical trials

Lilly says its obesity drugs helped patients lose weight in clinical trials Reuters

Lean: Center Fact-focusedFactuality: Very highCountry: United KingdomFunding: CorporateOwner: Thomson Reuters
+ 1 · Full coverage
Coverage breakdown
Funding
Corporate50%
Not recorded50%
Countries
United Kingdom50%
United States50%
Media ownership
Thomson Reuters50%
Amherst Bee50%
Avg reliability92
Low-credibility share0%
Fact / opinion3/0
State media0%
More analysis
Truth score: 57 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 2 Reliability: 92 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Health
2 sources

Who is covering this

ReutersCenterYahoo NewsCenter
Truth score 531
Centre 100%100%
ReutersCenter

Novo Nordisk's Wegovy pill beats forecasts as it battles Lilly

Novo Nordisk's Wegovy pill beats forecasts as it battles Lilly Reuters

Lean: Center Fact-focusedFactuality: Very highCountry: United KingdomFunding: CorporateOwner: Thomson Reuters
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United Kingdom50%
United States50%
Media ownership
Thomson Reuters50%
Apollo Global Management50%
Avg reliability81
Low-credibility share0%
Fact / opinion2/0
State media0%
More analysis
Truth score: 53 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 2 Reliability: 81 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Left 46%46%Centre 42%42%Right 12%12%
BBC NewsCenter

Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness

The US Food and Drug Administration says Ozempic, Wegovy, and other weight-loss drugs must have labels about the condition, known as NAION. Companies making popular weight loss drugs, including Ozempic and Wegovy, will be required to...

Lean: Center Fact-focusedFactuality: Very highCountry: United KingdomFunding: Public broadcasterOwner: BBC (UK Government)
+ 37 · Full coverage
Coverage breakdown
Funding
Corporate62%
Not recorded17%
Public broadcaster7%
Private7%
Nonprofit3%
Countries
United States76%
India14%
United Kingdom10%
Media ownership
Independent19%
Comcast12%
G/O Media12%
WSNS-TV6%
Google News6%
Avg reliability74
Low-credibility share4%
Fact / opinion42/0
State media0%
More analysis
Truth score: 91 (Strongly corroborated) Propaganda risk: 0 Trending: Low Sources: 29 Reliability: 74 Bias severity: 57 Risk: 4Sentiment: -95Sensationalism: 0 Amplification: 0

How we score

Like
Health
1 source

Who is covering this

Amherst BeeNot rated
Truth score 34
No rated outlets yet
Amherst BeeNot rated

Novo's investigational CagriSema, a GLP-1 and amylin analog, demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial, presented at ObesityWeek® 2026 and published in The Lancet Diabetes & Endocrinology

REDEFINE 9 trial showed CagriSema 1.7 mg / 1.7 mg and 1.0 mg / 1.0 mg produced estimated average weight loss of 20.7% and 21.0%, respectively, at 68 weeks, compared with 2.0% with placebo, in adults with overweight or obesity,…

Lean: Not rated Fact-focusedCountry: United States
Full coverage
Coverage breakdown
Funding
Not recorded100%
Countries
United States100%
Media ownership
Amherst Bee100%
Avg reliability-
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 34 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: Not rated Bias severity: 0 Risk: 0Sentiment: -100Sensationalism: 8 Amplification: 0

How we score

Like
Health
1 source

Who is covering this

QuartzLeans left
Truth score 40
Left 100%100%
QuartzLeans left

Novo Nordisk's weight loss injection cut obesity in young children, trial shows

In the STEP Young trial, BMI fell an estimated 17.4% with semaglutide and rose 2.2% with placebo at week 68 among children 6 to under 12

Lean: Leans left Fact-focusedFactuality: HighCountry: United StatesFunding: CorporateOwner: G/O Media
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
G/O Media100%
Avg reliability72
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 40 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 72 Bias severity: 0 Risk: 0Sentiment: -100Sensationalism: 0 Amplification: 0

How we score

Like
Business
3 sources
Truth score 58
Centre 100%100%
CNBCCenter

CVS Health plans to split itself up. Here's why a breakup could make sense now

Analysts say that after a roughly two-year turnaround the company's retail pharmacy business and other units may be strong enough to stand on their own. Covered by 3 outlets: 3 are centre.

Lean: Center Fact-focusedFactuality: HighCountry: United StatesFunding: Corporate
+ 1 · Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States67%
India33%
Media ownership
Independent33%
CNBC33%
Google News33%
Avg reliability78
Low-credibility share0%
Fact / opinion4/0
State media0%
More analysis
Truth score: 58 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 3 Reliability: 78 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 8 Amplification: 0

How we score

Like
Left 40%40%Centre 40%40%Right 20%20%
TIMELeans left

Weight-Loss Drugs May Help Sleep Apnea and Arthritis

Eli Lilly reported results from new studies exploring the effects of its GLP-1 weight-loss drugs on sleep apnea and arthritis. China has approved US pharmaceutical giant Eli Lilly’s weight-loss pill orforglipron, making it the country’s...

Lean: Leans left Fact-focusedFactuality: HighCountry: United StatesFunding: CorporateOwner: Marc Benioff
+ 2 · Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States60%
United Kingdom20%
Hong Kong20%
Media ownership
G/O Media20%
Thomson Reuters20%
Marc Benioff20%
Independent20%
Alibaba Group20%
Avg reliability77
Low-credibility share0%
Fact / opinion7/0
State media0%
More analysis
Truth score: 75 (Corroborated) Propaganda risk: 0 Trending: Low Sources: 5 Reliability: 77 Bias severity: 33 Risk: 0Sentiment: -29Sensationalism: 0 Amplification: 0

How we score

Like
Health
1 source

Who is covering this

CNBCCenter
Truth score 43
Centre 100%100%
CNBCCenter

Novo says Wegovy injection lowers BMI and obesity rates in children in trial

Wegovy is already approved to treat obesity in children ages 12 and older, but there are currently no approved medications for those under 12.

Lean: Center Fact-focusedFactuality: HighCountry: United StatesFunding: Corporate
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
CNBC100%
Avg reliability80
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 43 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 80 Bias severity: 0 Risk: 0Sentiment: 100Sensationalism: 0 Amplification: 0

How we score

Like
Crime and Justice
1 source

Who is covering this

ReutersCenter
Truth score 47
Centre 100%100%
ReutersCenter

Trial failures of Novartis, Novo Nordisk heart drugs leave experts guessing

Trial failures of Novartis, Novo Nordisk heart drugs leave experts guessing Reuters

Lean: Center Fact-focusedFactuality: Very highCountry: United KingdomFunding: CorporateOwner: Thomson Reuters
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United Kingdom100%
Media ownership
Thomson Reuters100%
Avg reliability92
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 47 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 92 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
1 source

Who is covering this

CNBCCenter
Truth score 43
Centre 100%100%
CNBCCenter

Novo raises full-year outlook as Wegovy pill sales impress

Novo posted quarterly earnings ahead of expectations early Wednesday as sales of its Wegovy pill blew past estimates

Lean: Center Fact-focusedFactuality: HighCountry: United StatesFunding: Corporate
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
CNBC100%
Avg reliability80
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 43 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 80 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Entertainment
1 source

Who is covering this

DeadlineCenter
Truth score 41
Centre 100%100%
DeadlineCenter

Narrative Global Sales Takes Three Genre Films To AFM Including Jenna Kanell Sci-Fi ‘De Novo’ With Lilly Wachowski Aboard

EXCLUSIVE: Lilly Wachowski’s Anarchists United with Sarah Marie Flores and Lawrence Mattis have joined the upcoming sci-fi film De Novo as executive producers. Written and directed by Terrifier actress Jenna Kanell, and currently in...

Lean: Center Fact-focusedFactuality: HighCountry: United StatesFunding: CorporateOwner: Penske Media Corporation
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
Penske Media Corporation100%
Avg reliability75
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 41 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 75 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Health
1 source

Who is covering this

MedscapeCenter
Truth score 38
Centre 100%100%
MedscapeCenter

DCBs Hold Their Own Against Stents in De Novo Lesions

In noncomplex coronary artery disease, a drug coated-balloon is noninferior to a drug-eluting stent at 12 months.

Lean: Center Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Independent
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
Independent100%
Avg reliability65
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 38 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 65 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Health
1 source

Who is covering this

MedpagetodayCenter
Truth score 38
Centre 100%100%
MedpagetodayCenter

Study Strengthens Case for Stent-Free PCI in De Novo Coronary Lesions

(MedPage Today) -- For de novo coronary lesions, drug-coated balloons (DCBs) were just as effective as standard drug-eluting stents, the TRANSFORM II trial showed. Among patients with native coronary lesions undergoing percutaneous...

Lean: Center Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Independent
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
Independent100%
Avg reliability65
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 38 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 65 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Technology
1 source

Who is covering this

ComputerweeklyCenter
Truth score 38
Centre 100%100%
ComputerweeklyCenter

Interview: Loïc Giraud, vice-president of data and AI foundation, Novo

<p>After spending time at a startup, Loïc Giraud, vice-president of the data and artificial intelligence (AI) foundation at healthcare and pharmaceutical company Novo, returned to what he knows best just over two years ago – helping a...

Lean: Center Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Independent
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
Independent100%
Avg reliability65
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 38 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 65 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Business
1 source

Who is covering this

The GuardianLeft
Truth score 45
Left 100%100%
The GuardianLeft

Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn

GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes...

Lean: Left Fact-focusedFactuality: Very highCountry: United KingdomFunding: Nonprofit trustOwner: Scott Trust
Full coverage
Coverage breakdown
Funding
Nonprofit trust100%
Countries
United Kingdom100%
Media ownership
Scott Trust100%
Avg reliability85
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 45 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 85 Bias severity: 0 Risk: 0Sentiment: -100Sensationalism: 0 Amplification: 0

How we score

Like
World
1 source

Who is covering this

The Epoch TimesRight
Truth score 17Factuality: Low
Right 100%100%
The Epoch TimesRight

First Weight-Loss Tablet Approved for Use in Australia

Low reliability sourceElevated risk

A sign bearing the logo of Novo Nordisk next to the company's factory in Hillerod, Denmark, on Nov. 12, 2025. (Sergei Gapon/AFP via Getty Images)

Lean: Right Fact-focusedFactuality: LowCountry: United StatesFunding: PrivateOwner: Epoch Media Group
Full coverage
Coverage breakdown
Funding
Private100%
Countries
United States100%
Media ownership
Epoch Media Group100%
Avg reliability35
Low-credibility share100%
Fact / opinion1/0
State media0%
More analysis
Truth score: 17 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 35 Bias severity: 0 Risk: 100Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Science
1 source

Who is covering this

NatureNo political lean
Truth score 34
No rated outlets yet
NatureNo political lean

China plans ban on biotech exports

Nature Biotechnology, Published online: 10 November 2026; doi:10.1038/s41587-026-03397-6 China plans ban on biotech exports

Lean: No political lean Fact-focusedCountry: United StatesFunding: CorporateOwner: Independent
+ 4 · Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
Independent100%
Avg reliability-
Low-credibility share0%
Fact / opinion5/0
State media0%
More analysis
Truth score: 34 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: Not rated Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like